Clinical Data MSD, Eisai report setback in first-line kidney cancer trial PharmaphorumThe LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Gilead, Arcus tumble again in TIGIT, triggering 2 trial cullsNext: AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
